R&D | December 05, 2025
Peapod Bio teams up with Enamine to supercharge drug discovery
Peapod Bio’s proprietary technologies can efficiently identify inhibitors and binding molecules for virtually any target
Peapod Bio’s proprietary technologies can efficiently identify inhibitors and binding molecules for virtually any target
The technology is intended to support imaging-based training, protocol optimisation and surgical planning
The company introduced the ExcelSign E12 and E17 modular patient monitors, the Relife 1000 biphasic defibrillator, and a new OT charting software
The agreement allows Biocon Biologics to commercialize both its Denosumab biosimilars (Vevzuo and Evfraxy) in Europe starting December 2, 2025
Suffering from acute migraine? You may soon bid adieu to the debilitating headache
Despite steep funding setbacks, the global HIV response has gained momentum in 2025 with the introduction of twice-yearly injectable LEN
Armlupeg is indicated for decrease the incidence of infection, as manifested by febrile neutropenia, in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs
Ascelis Center of Excellence for Peptide Development and Characterization will drive the development of cosmetic, therapeutic, and pharmaceutical peptides
Subscribe To Our Newsletter & Stay Updated
